A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

Phase 3

Completed

• Conditions: COPD, Chronic Obstructive Pulmonary Disease
• Interventions: Drug: GP MDI (PT001) 14.4 μg; Drug: FF MDI (PT005) 9.6 μg

• Registration Number: NCT02937584
• Lead Sponsor: Pearl Therapeutics, Inc.

Brief Summary

To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to severe chronic obstructive pulmonary disease (COPD) following chronic dosing after approximately two weeks treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-17
• Study First Submitted QC: 2016-10-17
• Study First Posted: 2016-10-18
• Study Start: 2016-12-29
• Primary Completion: 2018-05-28
• Study Completion: 2018-05-28
• Results First Submitted: 2019-05-10
• Status Verified: 2019-06
• Results First Submitted QC: 2019-06-28
• Last Update Submitted: 2019-06-28
• Results First Posted: 2019-07-24
• Last Update Posted: 2019-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or Child bearing potential, has a negative urine pregnancy test at Visit 1, and agrees to use acceptable contraceptive methods used consistently and correctly
• Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
• Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
• At Visit 1, FEV1/FVC ratio must be <0.70
• At Visit 1, post-bronchodilator FEV1must be >30% and <80% predicted normal value, calculated using The Third National Health and Nutrition Examination Survey (NHANES III) reference equations.

Exclusion criteria:

• Significant diseases other than COPD, i.e., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
• Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.
• Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
• Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).
• Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).
• Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated.
• Subjects who have a history of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
GP MDI (PT001) 14.4 μg	GP MDI (PT001) 14.4 μg	Glycopyrronium
FF MDI (PT005) 9.6 μg	FF MDI (PT005) 9.6 μg	Formoterol Fumarate

Primary Outcome Measures

Name	Time	Method
Specific Image-Based Airway Volume (siVaw)	Baseline, Day 15	Specific image-based airway volume. Average across lobe, adjusted for lobe volume. Ratio to baseline
Specific Image-based Airway Resistance (siRaw)	Baseline, Day 15	Specific image-based airway resistance (siRaw). Average across lobes, adjusted for lobe volume. Ratio to baseline.

Secondary Outcome Measures

Name	Time	Method
FEV1	Baseline, Day 15	FEV1 Change from baseline in Forced Expiratory Volume at 1 second.
Image-based Airway Resistance (iRaw)	Baseline, Day 15	Image-based airway resistance (iRaw) without correction for lobe volume. Ratio to baseline.
Image-based Airway Volume (iVaw)	Baseline, Day 15	Image-based airway volume (iVaw) without correction for lobe volume. Ratio to baseline.
Functional Residual Capacity (FRC)	Baseline, Day 15	Functional residual capacity (FRC). Ratio to baseline.

Trial Locations

Locations (1)

Research Site; 🇧🇪 Erpent, Belgium